*The safety and efficacy for GAD in 7 to 17 years of age was demonstrated in one 10-week, placebo-controlled trial (n=272) *Safety and effectiveness in pediatric patients less than 7 years have not been established. *The most frequently observed ARs in the pediatric trials included nausea, headache, weight reduction, and abdominal pain *Weight and height should be regularly monitored in children and adolescents treated with duloxetine *The average steady-state duloxetine concentration was about 30% lower in children and adolescents relative to adults
|